A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Hydroxocobalamin (Cyanokit)

Antidote class · 1 generic manufacturer · 1 ANDAs filed at FDA.

First FDA approval2010-11-12
Generic availableYes · 1 mfrs
Shortage statusActive shortage
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.814/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.814
Across all dosage forms in distribution.
Highest NADAC
$0.814
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Hydroxocobalamin used for?

Hydroxocobalamin is a Antidote medication tracked in Medicare Part D.

Is there a generic for Hydroxocobalamin?

Yes. 1 ANDAs filed at FDA, 1 generic manufacturers currently shipping.

How much does my plan pay for Hydroxocobalamin?

Across 329 Part D plans, Hydroxocobalamin averages $0.814/unit (NADAC). Lowest available: $0.814/unit. Highest in distribution: $0.814/unit.

Is Hydroxocobalamin on the FDA shortage list?

Yes. Hydroxocobalamin is currently listed as an active FDA shortage.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Antidote2 alternatives in D1
01
Acetylcysteine
Brand: ACETADOTE
$0.643Lowest NADAC
13Generic mfrs
$3.0MCY24 Part D spend
Compare →
02
Fomepizole
Antidote
Lowest NADAC
4Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.